# A semaglutide reading list

> Studies | Personalized telemedicine — The personalized telemedicine reading list: published semaglutide studies on appetite, weight, cardiovascular outcomes, safety and longer treatment.

Appetite biology, the weight result, the cardiovascular record and longer treatment.

## Experimental appetite research

The [rodent experiments on distributed neural pathways](https://pubmed.ncbi.nlm.nih.gov/32213703/) describe changes in food intake and preference without a decrease in energy expenditure. The human starting point is [STEP 1 in adults with overweight or obesity without diabetes](https://pubmed.ncbi.nlm.nih.gov/33567185/). These lead into the [appetite essay](/appetite).

The relation between the rodent and human findings is my particular preoccupation. One describes experimental biology in mice and rats; the other reports a human weight outcome. The [dedicated safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) belongs beside them because it discusses treatment burdens and the risk–benefit profile in type 2 diabetes.

## Cardiovascular populations

[SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/) concerns established cardiovascular disease and overweight or obesity without diabetes. [SUSTAIN-6](https://pubmed.ncbi.nlm.nih.gov/27633186/) concerns type 2 diabetes at high cardiovascular risk, including its reported eye-complication signal. [STEP-HFpEF](https://pubmed.ncbi.nlm.nih.gov/37622681/) concerns obesity-related heart failure with preserved ejection fraction, symptoms and physical limitations.

Together these are the main reading for the [cardiovascular essay](/heart-outcomes). Their separate populations are part of their interest. Flattening that variety into a single statement about heart health would erase the circumstances that give the results their particular meaning for me.

## Treatment duration

The [longer on-treatment observation in STEP 5](https://pubmed.ncbi.nlm.nih.gov/36216945/) sits beside [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/) in the [essay on time](/long-term-weight). The sustained reduction in weight over 104 weeks gives the duration question a concrete place in the discussion.

I put considerable value on the time spent observing a result. The amount of change and its persistence during treatment each deserve attention. The list below gathers the source titles; each paper comes with its own population, circumstance and outcome.

## References

[1] Once-Weekly Semaglutide in Adults with Overweight or Obesity https://pubmed.ncbi.nlm.nih.gov/33567185/
[2] Semaglutide lowers body weight in rodents via distributed neural pathways https://pubmed.ncbi.nlm.nih.gov/32213703/
[3] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/
[4] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27633186/
[5] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/
[6] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial https://pubmed.ncbi.nlm.nih.gov/36216945/
[7] Safety of Semaglutide https://pubmed.ncbi.nlm.nih.gov/34305810/

---

I follow semaglutide through published research here; Personalized Telemedicine is an essay site with no medical business behind the name, and nothing on these pages is medical advice.